Ibuprofen product-specific bioequivalence guidance EMA [Regulatives / Guidelines]

posted by qualityassurance – Jordan, 2021-09-26 09:45 (492 d 22:48 ago) – Posting: # 22599
Views: 1,744

Dear Forum members,

The question is related to product-specific bioequivalence guidance (EMA) for Ibuprofen draft and Final.

The former indicates that the method should be enantioselective and the later indicates the opposite. Of course we should consider the final guidance and not the draft.

However, all conditions are fulfilled for (⇒ chiral analytics) and also found some public assessment report where chiral method was used and Pharmacokinetic data were submitted for both enantiomers.

Please suggest, whether we should go for chiral or achiral assay?

Thank you.

Complete thread:

UA Flag
Activity
 Admin contact
22,477 posts in 4,708 threads, 1,603 registered users;
17 visitors (0 registered, 17 guests [including 8 identified bots]).
Forum time: 07:34 CET (Europe/Vienna)

I think it is much more interesting to live with uncertainty
than to live with answers that might be wrong.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5